These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27256111)

  • 1. Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC.
    Kim BY; Jeong S; Lee SY; Lee SM; Gweon EJ; Ahn H; Kim J; Chung SK
    Exp Mol Med; 2016 Jun; 48(6):e237. PubMed ID: 27256111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.
    Hamasaki M; Hashizume Y; Yamada Y; Katayama T; Hohjoh H; Fusaki N; Nakashima Y; Furuya H; Haga N; Takami Y; Era T
    Stem Cells; 2012 Nov; 30(11):2437-49. PubMed ID: 22949078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
    Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
    Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence.
    Hayashi Y; Hsiao EC; Sami S; Lancero M; Schlieve CR; Nguyen T; Yano K; Nagahashi A; Ikeya M; Matsumoto Y; Nishimura K; Fukuda A; Hisatake K; Tomoda K; Asaka I; Toguchida J; Conklin BR; Yamanaka S
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13057-13062. PubMed ID: 27794120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G > A in the ACVR1 gene.
    Huang X; Roeder A; Li R; Beers J; Liu C; Zou J; Yu PB; Zheng W
    Stem Cell Res; 2021 Jul; 54():102424. PubMed ID: 34139597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva.
    Shi S; Cai J; de Gorter DJ; Sanchez-Duffhues G; Kemaladewi DU; Hoogaars WM; Aartsma-Rus A; 't Hoen PA; ten Dijke P
    PLoS One; 2013; 8(7):e69096. PubMed ID: 23861958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
    Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
    Takahashi M; Katagiri T; Furuya H; Hohjoh H
    Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
    Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
    J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation.
    Lin H; Ying Y; Wang YY; Wang G; Jiang SS; Huang D; Luo L; Chen YG; Gerstenfeld LC; Luo Z
    Biochim Biophys Acta Mol Cell Res; 2017 Dec; 1864(12):2369-2377. PubMed ID: 28847510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
    Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
    Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
    J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
    Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
    Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrodysplasia ossificans progressiva with minor unilateral hallux anomaly in a sporadic case from Northern Tanzania with the common ACVR1c.617G>A mutation.
    Saleh M; Commandeur J; Bocciardi R; Kinabo G; Hamel B
    Pan Afr Med J; 2015; 22():299. PubMed ID: 26966495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Protocol to Optimize iPS Cells for Genome Analysis of Fibrodysplasia Ossificans Progressiva.
    Matsumoto Y; Ikeya M; Hino K; Horigome K; Fukuta M; Watanabe M; Nagata S; Yamamoto T; Otsuka T; Toguchida J
    Stem Cells; 2015 Jun; 33(6):1730-42. PubMed ID: 25773749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
    Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
    Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.
    Towler OW; Shore EM; Xu M; Bamford A; Anderson I; Pignolo RJ; Kaplan FS
    Eur J Med Genet; 2017 Jul; 60(7):399-402. PubMed ID: 28473268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.